Printed from Voxsanity (voxsanity.com.au) — NCT07177352 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have noticed memory problems in themselves, or whose close contacts have noticed memory concerns in them, within the past year — this applies whether or not a doctor has previously diagnosed them with mild cognitive impairment (MCI) or dementia related to Alzheimer's disease.
Who may not be able to join:
People who need significant help with basic everyday tasks (such as eating, dressing, or bathing) because of cognitive impairment.
People whose vision or hearing problems would prevent them from completing the memory and thinking tests required by the trial (note: glasses and hearing aids are allowed).
People who have reported, or have a known diagnosis of, a brain or nervous system condition — other than Alzheimer's disease — that may cause memory or thinking problems.
People with a history of severe, significant brain injury.
People with a serious medical condition that a trial site's medical team determines would make safe participation or completion of the study unlikely.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Royal Prince Alfred Hospital, Camperdown, New South Wales
St Vincent's Hospital Sydney, Darlinghurst, New South Wales
Southern Neurology, Kogarah, New South Wales
KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales
Flinders Medical Centre, Bedford Park, South Australia
Queen Elizabeth Hospital, Woodville, South Australia
Box Hill Hospital, Box Hill, Victoria
Heidelberg Repatriation Hospital, Heidelberg, Victoria
Alfred Health, Melbourne, Victoria
Royal Melbourne Hospital, Parkville, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07177352
Sponsor: Hoffmann-La Roche
Phase: Phase 3
Status: Recruiting
Condition: Alzheimer's Disease
Trial contact: 888-662-6728 (U.S. and Canada)
More information: https://clinicaltrials.gov/study/NCT07177352
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have noticed memory problems in themselves, or whose close contacts have noticed memory concerns in them, within the past year — this applies whether or not a doctor has previously diagnosed them with mild cognitive impairment (MCI) or dementia related to Alzheimer's disease.
Who may not be able to join:
People who need significant help with basic everyday tasks (such as eating, dressing, or bathing) because of cognitive impairment.
People whose vision or hearing problems would prevent them from completing the memory and thinking tests required by the trial (note: glasses and hearing aids are allowed).
People who have reported, or have a known diagnosis of, a brain or nervous system condition — other than Alzheimer's disease — that may cause memory or thinking problems.
People with a history of severe, significant brain injury.
People with a serious medical condition that a trial site's medical team determines would make safe participation or completion of the study unlikely.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇩🇰 Denmark
🇮🇹 Italy
🇯🇵 Japan
🇵🇱 Poland
Puerto Rico
🇰🇷 South Korea
🇪🇸 Spain
🇹🇼 Taiwan
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Concentration of pTau217 in Blood on Day1; Cognitive score in ISLT on Day 1
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.